Immunosuppressants - Egypt

Egypt

Highlights

In Egypt, the Immunosuppressants market is anticipated to achieve a revenue of US$42.32m by the year 2024.
It is projected to experience a compound annual growth rate (CAGR 2024-2029) of 17.22%, leading to a market volume of US$93.68m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, estimated to be US$35.47bn in 2024.
Egypt's demand for immunosuppressants has been steadily increasing, driven by the rising prevalence of autoimmune diseases in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for immunosuppressants in Egypt has been on the rise in recent years.

Customer preferences: Egypt has a high incidence of autoimmune diseases, which has led to an increased demand for immunosuppressants. Patients suffering from autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis require immunosuppressants to manage their conditions. Additionally, the country has a high prevalence of organ transplant recipients who require immunosuppressants to prevent organ rejection.

Trends in the market: The market for immunosuppressants in Egypt is expected to continue growing as the country's population ages and the incidence of autoimmune diseases increases. The market is also expected to benefit from the increasing availability of generic immunosuppressants, which are more affordable than branded drugs. The high cost of branded drugs has been a barrier to access for many patients, but the availability of generic drugs is expected to improve affordability and access.

Local special circumstances: Egypt has a large population of low-income individuals who may not be able to afford branded immunosuppressants. The availability of generic drugs is expected to improve access to these life-saving medications for these individuals. Additionally, the country has a shortage of healthcare professionals, which can make it difficult for patients to access the care they need.

Underlying macroeconomic factors: Egypt's economy has been growing in recent years, which has led to an increase in healthcare spending. The government has been investing in healthcare infrastructure and increasing access to healthcare services. Additionally, the country has a large and growing population, which is expected to drive demand for healthcare services, including immunosuppressants. However, the country is still facing economic challenges, including high inflation and a large budget deficit, which could impact healthcare spending in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.